Patents Assigned to Adienne SRL
  • Anti-C5 Alpha Antibodies
    Publication number: 20130071922
    Abstract: The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system.
    Type: Application
    Filed: September 12, 2012
    Publication date: March 21, 2013
    Applicant: Adienne SRL
    Inventors: Francesco TEDESCO, Roberto Marzari
  • Methods of treating a disease with anti-C5 alpha antibodies
    Patent number: 8282929
    Abstract: The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterized by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: October 9, 2012
    Assignee: Adienne SRL
    Inventors: Francesco Tedesco, Roberto Marzari
  • Anti-C5 alpha antibodies
    Patent number: 7999081
    Abstract: The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system.
    Type: Grant
    Filed: July 10, 2003
    Date of Patent: August 16, 2011
    Assignee: Adienne SRL
    Inventors: Francesco Tedesco, Roberto Marzari